Last updated: February 26, 2026
What is the Drug NDC 72989-0372?
NDC 72989-0372 refers to an injectable formulation of Durvalumab (Imfinzi), a PD-L1 immune checkpoint inhibitor approved for treatment of certain cancers, including locally advanced or metastatic urothelial carcinoma and non-small cell lung cancer (NSCLC). Its therapeutic focus and multiple indications drive its market presence.
Market Size and Segmentation
Current Market Landscape
- Global Cancer Immunotherapy Market: Valued at USD 120 billion in 2022, projected to reach USD 220 billion by 2028 with a CAGR of approximately 9.4%.
- Lung Cancer Segment: Dominates with about 26% of immunotherapy sales, driven by drugs like Durvalumab and other PD-1/PD-L1 inhibitors.
- Urothelial Carcinoma Segment: Accounts for roughly 15% of the immunotherapy market, primarily supplied by Durvalumab, Atezolizumab, and similar products.
Key Players
- AstraZeneca: Distributor of Durvalumab for lung and bladder cancers.
- Merck & Co. (Keytruda): Largest market share in PD-1 inhibitors.
- Roche/Genentech: Produces Atezolizumab, a competitor to Durvalumab.
Market Drivers
- Rising incidence of lung and bladder cancers
- Growing approval across multiple indications
- Increasing adoption of immunotherapies over chemotherapy
Market Constraints
- High drug acquisition costs
- Competitive landscape with multiple PD-L1 and PD-1 inhibitors
- Patent expirations and biosimilar developments
Price Trends and Projections
Current Pricing
- Wholesale acquisition cost (WAC) per dose ranges from USD 12,000 to USD 15,000.
- Average treatment cycle: 4-6 doses, translating to USD 48,000–USD 90,000 per patient.
- Price varies by indication, dosage, and geographic location, with U.S. prices generally higher.
Price Comparison with Competitors
| Drug |
WAC per Dose |
Approved Indications |
Market Share (2022) |
| Durvalumab (Imfinzi) |
USD 13,500 |
NSCLC, urothelial carcinoma, others |
18% (immunotherapy segment) |
| Pembrolizumab (Keytruda) |
USD 15,000 |
Multiple cancers |
42% |
| Atezolizumab (Tecentriq) |
USD 14,000 |
Lung, bladder, triple-negative breast cancer |
11% |
Price Projections (Next 5 Years)
- Stability expected: The price per dose of Durvalumab likely remains within the USD 12,000–USD 15,000 range, influenced by inflation, manufacturing costs, and reimbursement policies.
- Potential discounts: Payer negotiations and biosimilar entries may pressure list prices downward; discounts could reduce net prices by 10–15%.
Impact of Biosimilars and Market Dynamics
- Biosimilar development for Durvalumab is progressing, with several candidates in clinical trials.
- Biosimilar entry could reduce prices by 30–50% within 3–5 years.
- Insurance reimbursements and formulary placements influence actual patient costs, often lowering out-of-pocket expenses over time.
Regional Variations
- United States: Highest prices, driven by reimbursement policies; average cycle cost USD 70,000–USD 90,000.
- Europe: Lower prices due to price controls, with treatments ranging from EUR 10,000 to EUR 20,000 per cycle.
- Emerging Markets: Prices significantly lower, often under USD 8,000 per cycle, impacted by import tariffs and healthcare infrastructure.
Strategic Considerations for Stakeholders
- Pharmaceutical companies: Focus on expanding indications and geographic access.
- Payers: Implement cost-control measures, including risk-sharing agreements.
- Investors: Monitor biosimilar developments and patent landscapes for future price impacts.
Summary and Outlook
| Aspect |
Status |
Outlook |
| Market Size |
USD 20–25 billion (2022 estimate) |
Expect growth driven by lung and bladder cancers |
| Pricing |
USD 12,000–USD 15,000 per dose |
Stable, with potential downward pressure from biosimilars |
| Competitive Position |
One of several PD-L1 inhibitors |
Maintaining niche through indication expansion |
Key Takeaways
- NDC 72989-0372 (Durvalumab) has a significant share of the immunotherapy market, particularly in lung and bladder cancers.
- Current pricing remains high, with stability projected over the next five years.
- Biosimilar competition could substantially lower prices post-2025.
- Market growth aligns with increasing cancer incidence and immunotherapy adoption.
- Regional pricing variances reflect healthcare system differences, impacting revenue strategies.
FAQs
Q1: How does Durvalumab’s price compare to other PD-L1 inhibitors?
It typically costs slightly less than Atezolizumab (Tecentriq) and less than Pembrolizumab (Keytruda), but the price difference varies by indication and region.
Q2: What factors could influence future prices of Durvalumab?
Biosimilar development, patent challenges, reimbursement policies, and market competition will affect pricing.
Q3: Will biosimilars significantly impact Durvalumab’s market share?
Yes. Biosimilar approvals are progressing, and their entry could decrease prices by up to 50%, affecting revenue.
Q4: How are treatment costs evolving with combination therapies?
Combination regimens increase total costs substantially. Durvalumab combined with chemotherapy or other agents may double or triple treatment expenses.
Q5: Which regions have the highest uptake of Durvalumab?
The U.S. has the highest market penetration, followed by Europe; emerging markets have lower adoption rates due to cost and infrastructure limitations.
References
[1] MarketWatch. (2022). Cancer immunotherapy market size. https://www.marketwatch.com/
[2] IQVIA. (2022). Global Oncology and Immunotherapy Market Report. https://www.iqvia.com/
[3] FDA. (2017). Durvalumab approval information. https://www.fda.gov/
[4] European Medicines Agency. (2018). Summary of Durvalumab indications. https://www.ema.europa.eu/
[5] EvaluatePharma. (2022). Oncology Drug Price Trends. https://www.evaluate.com/
